drugset
drugset / Trial / NCT06663722

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT06663722 ↗

Phase 2 Recruiting 49 enrolled University of Miami Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).

Timeline

Start
2025-05-05
Primary completion
2030-05-05
Completion
2030-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Axatilimab Monoclonal antibody 0.3 mg/kg Intravenous

Indications

chronic graft versus host disease